Related Experiment Videos

Potential factors influencing carbapenem activity against Bacteroides fragilis group isolates

J P Iaconis¹, H L Nadler, W Sheikh

¹Zeneca Pharmaceuticals Group, Wilmington, Delaware 19897, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America

|June 1, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Comparative in vitro activities of ceftaroline and ceftriaxone against bacterial pathogens associated with respiratory tract infections: results from the AWARE surveillance study.

The Journal of antimicrobial chemotherapy·2016

Convalescent phase outpatient parenteral antiinfective therapy for children with complicated appendicitis.

The Pediatric infectious disease journal·2001

Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.

The American journal of medicine·1998

Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Antimicrobial agents and chemotherapy·1998

A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus.

The Journal of antimicrobial chemotherapy·1997

Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1997

See all related articles